Evotec (EVO) Stock Price, News & Analysis

Company Overview

Evotec SE (NASDAQ:EVO) is a global drug discovery and development alliance company headquartered in Hamburg, Germany. Specializing in end-to-end solutions for pharmaceutical and biotechnology partners, Evotec operates at the intersection of biology, chemistry and translational medicine. The company’s integrated platform spans target identification and validation, assay development, high-throughput screening, medicinal chemistry, and preclinical development, enabling clients to progress therapeutic candidates efficiently from early research through to clinical studies.

Central to Evotec’s offering are its proprietary technologies and expertise in cell-based screening, protein sciences, in vivo pharmacology, and advanced ADME/DMPK services. The company collaborates with leading global pharma firms, biotech innovators, and academic institutions under risk- and reward-sharing partnerships. Through a combination of fee-for-service arrangements and milestone-driven alliances, Evotec aligns its incentives with those of its partners, driving shared commitment to program success and accelerating timelines to proof of concept.

Evotec maintains a broad international footprint with research and development sites across Europe, North America and Asia. Key locations include Hamburg, Munich and Toulouse in Europe, South San Francisco, Boston and Toronto in North America, as well as Shanghai and Pune in Asia. The company has supplemented its internal capabilities through strategic acquisitions, integrating specialized firms in drug metabolism (Cyprotex), iPSC technologies (Just), medicinal chemistry (Aptuit) and small-molecule screening tools under its OpnMe platform.

Founded in 1993 through the consolidation of several European biotech ventures, Evotec has grown steadily under the leadership of Chief Executive Officer Dr. Werner Lanthaler, who joined the firm in 2008 and has overseen its transformation into a fully integrated discovery engine. With a focus on innovation and technology-driven solutions, Evotec continues to invest in data science, artificial intelligence and precision medicine approaches to address unmet medical needs across therapeutic areas such as neuroscience, inflammation, oncology, and metabolic diseases.

Key Stats

• Today's Range: $4.07 to $4.14
• 50-Day Range: $3.76 to $4.73
• 52-Week Range: $2.84 to $5.64
• Volume: 29,350 shs
• Average Volume: 135,894 shs
• Market Capitalization: $1.45 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.93
• Consensus Rating: Hold

Evotec Stock Analysis - MarketRank™

Evotec scored higher than 40% of companies evaluated by MarketBeat, and ranked 687th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Evotec has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Evotec has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Evotec are expected to grow in the coming year, from ($0.41) to ($0.18) per share.

Price to Book Value per Share Ratio

Evotec has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.21% of the float of Evotec has been sold short.

Short Interest Ratio / Days to Cover

Evotec has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Evotec has recently decreased by 8.23%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evotec does not currently pay a dividend.

Dividend Growth

Evotec does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.21% of the float of Evotec has been sold short.

Short Interest Ratio / Days to Cover

Evotec has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Evotec has recently decreased by 8.23%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.94

News Sentiment

Evotec has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Evotec this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for EVO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Evotec to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evotec insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.00% of the stock of Evotec is held by insiders.

Percentage Held by Institutions

Only 5.81% of the stock of Evotec is held by institutions.

EVO Stock Analysis - Frequently Asked Questions

How have EVO shares performed this year?

Evotec's stock was trading at $4.16 at the start of the year. Since then, EVO stock has decreased by 2.2% and is now trading at $4.07.

When did Evotec IPO?

Evotec (EVO) raised $435 million in an IPO on Thursday, November 4th 2021. The company issued 20,000,000 shares at $21.75 per share.

Who are Evotec's major shareholders?

Evotec's top institutional shareholders include UMB Bank n.a..

How do I buy shares of Evotec?

Shares of EVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Evotec own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evotec investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), American Water Works (AWK) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Today: 7/12/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EVO
• CIK: 1412558
• Web: www.evotec.com
• Phone: 49-40-560-81-0
• Fax: 49-40-5608-1222
• Employees: 4,827
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Evotec: $5.93
• High Price Target: $8.00
• Low Price Target: $3.80
• Potential Upside/Downside: +45.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$212.18 million
• Net Margins: -26.34%
• Pretax Margin: -25.08%
• Return on Equity: -21.51%
• Return on Assets: -10.54%

Debt

• Debt-to-Equity Ratio: 0.46
• Current Ratio: 2.03
• Quick Ratio: 1.93

Sales & Book Value

• Annual Sales: $862.40 million
• Price / Sales: 1.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.91 per share
• Price / Book: 1.40

Miscellaneous

• Outstanding Shares: 355,110,000
• Free Float: 351,556,000
• Market Cap: $1.45 billion
• Optionable: Not Optionable
• Beta: 1.66